Early Detection and Diagnosis

You have full text access to this OnlineOpen article

Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST)

  1. Marie-Hélène Mayrand1,2,
  2. Eliane Duarte-Franco1,3,
  3. François Coutlée1,4,
  4. Isabel Rodrigues5,
  5. Stephen D. Walter6,
  6. Sam Ratnam7,
  7. Eduardo L. Franco1,†,*,
  8. for the CCCaST Study Group‡

Article first published online: 29 MAR 2006

DOI: 10.1002/ijc.21897

Issue

International Journal of Cancer

International Journal of Cancer

Volume 119, Issue 3, pages 615–623, 1 August 2006

Additional Information

How to Cite

Mayrand, M.-H., Duarte-Franco, E., Coutlée, F., Rodrigues, I., Walter, S. D., Ratnam, S., Franco, E. L. and for the CCCaST Study Group (2006), Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int. J. Cancer, 119: 615–623. doi: 10.1002/ijc.21897

Author Information

  1. 1

    Division of Cancer Epidemiology, Departments of Oncology and Epidemiology & Biostatistics, McGill University,Montreal, QC, Canada

  2. 2

    Département d'Obstétrique-Gynécologie, Université de Montréal, Montreal, QC, Canada

  3. 3

    Department of Family Medicine, McGill University, Montreal, QC Canada

  4. 4

    Département de Microbiologie-Infectiologie, Hôpital Notre-Dame du Centre Hospitalier Universitaire de l'Universitéde Montréal, Montreal, QC, Canada

  5. 5

    Département de Médecine familiale, Université de Montréal, Montreal, QC, Canada

  6. 6

    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

  7. 7

    Newfoundland Public Health Laboratory, St. John's, NF, Canada

  1. †

    Fax: +514-398-5002.

  2. ‡

    CCCaST Study Group.Montreal Research Staff: L. Abruzzese, K. Bellegarde, M. Bernardin, F. Ferdinand, G. Kelsal, M. Paquin, S. Piché, J. Poirier, A. Rodrigues, N. Rousseau, C. Schwartz, N. Slavtcheva E. Tunistky.St. John's Research Staff: G. Condon, D. Mason, B. Halfyard, J. McGrath, A. Batstone, W. Shea, C. Leonard, E. Oates, V. Moulton, P. Francis, C. Head, A. Fitzpatrick.Montreal Clinical Collaborators: M.Y. Arsenault, G. Asselin, L. Authier, S. Bagga, P. Bastien, L. Bazinet, F. Beaudoin, P. Beaulieu, M.J. Bédard, S. Belinski, S. Bélisle, J. Benoit, M. Bernard, S. Bianki, L. Biron, F. Bissonnette, R. Bou-Habib, J. Bourque, B. Bradbury, M. Champagne, Y. Charles, P. Choquette, J. N. Couture, H.Q. Dao, J. Desjardins, C. Desjardins, L. Desrosiers, S. DiTommaso, L. Dontigny, M. Doyle, J. Dubé, M.J. Dupuis, F. Durocher, F. Engel, B. Fafard, A. Ferenczy, G. Fortier, A. Fortin, C. Fortin, D. Francoeur, D. Frechette, P. Fugère, G. Gagné, G.P. Gagné, S. Gascon, M.J. Gaudreau, D. Gaudron, K. Gemayel, L. Gilbert, S. Gilbert, J. Gill, I. Girard, A. Gobeil, L. Granger, F. Grou, E. Grou, G. Guertin, J. Guimond, R. Hemmings, N. Ifergan, L. Johnson, C. Johnson, L. Ketchian, Y. Korcaz, C. Lafortune, J. Lalande, J.F. Lanctot, D. Landry, M. Landry, D. Langevin, I. Langlois, L. Lanmy-Monnot, L. Lapensée, L. Larouche, D. Laurin, M.C. Lavigne, Y. Lavoie, M. Leduc, F. Leger, N. Leroux, G. Luskey, N. Mansour, J. Marceau, A. Masse, M.H. Mayrand, I. Mayrand, L.R. McLauchlin, S. Menard, C. Mercer, M. Messier, B. Michon, M. Nadeau, M. Nguyen, S. Ouellet, C. Paquin, R. Paré, S. Peloquin, Y. Piché, R. Pichet, C. Rivard, I. Rodrigues, S. Roman, L. Rusimovic, G. Sanche, D. Souliere, D. Sproule, M. Steben, S. Still, D. Theriault, G. Tondreau, D. Tremblay, T. Minh Dung Vo, V.M. Whitehead, M. Yaffe, A. Di Zazzo, C. Ziegler.Newfoundland Clinical Collaborators: L. Dawson, D. Fontaine, J. Dunne, N. Kum, C. Pike, P. Power, P. Wadden, E. Bannister, E. Callahan, J. Collingwood, P. Crocker, A. Drover, F. Fifield, J. Fitzgerald, B. Grandy, M. Greene, K. Halley, L. Hatcher, J. Hickey, P. Horwood, J. Janes, F. Jardine, L. Kieley, S. King, C. Kirby, E. Mate, S. McGrath, C. McManamon, K. Misik, M. O'Dea, P. O'Shea, C. Peddle, M. Penton, L. Rogers, K. Saunders, P. Skirving, T. Sullivan, J. Verge, M. Watson, M. Young.

*Division of Cancer Epidemiology, McGill University, 546 Pine Avenue West, Montréal, Québec, Canada H2W 1S6

Publication History

  1. Issue published online: 8 MAY 2006
  2. Article first published online: 29 MAR 2006
  3. Manuscript Accepted: 18 JAN 2006
  4. Manuscript Received: 7 OCT 2005

Funded by

  • Canadian Institutes of Health Research
  • Canadian Institutes of Health Research (CIHR). Grant Number: MCT-54063
  • National Cancer Institute of Canada
  • CIHR
  • Fonds de la Recherche en Santé du Québec

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (403K)

References

  • 1
    Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J 2001; 164: 1017–25.
  • 2
    Nanda K, McCrory DC, Myers ER, Bastian A, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Int Med 2000; 132: 810–19.
  • 3
    IARC Working Group. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 64. Lyon: International Agency for Research on Cancer, 1995.
  • 4
    Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer JLM, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–19.
    Direct Link:
  • 5
    Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999; 91: 506–11.
  • 6
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen U. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645–51.
  • 7
    Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757–65.
  • 8
    Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002; 287: 2382–90.
  • 9
    Franco EL. Chapter 13: primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 2003; 31: 89–96.
  • 10
    Miller AB, Anderson G, Brisson J, Laidlaw J, Lepitre N, Malcolmson P, Mirwaldt P, Stuart G, Sullivan W. Report of a national workshop on screening for cancer of the cervix. Can Med Assoc J 1991; 145: 1301–24.
  • 11
    Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright TJ, Young N, Forum Group Members, Bethesda 2001 Workshop. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114–9.
  • 12
    Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000; 9: 945–51.
  • 13
    Castellsague X, Munoz N. Cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; 31: 20–8.
  • 14
    Castle PE, Giuliano AR. Chapter 4: genital tract infections, cervical inflammation, and antioxidant nutrients—assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 2003; 31: 29–34.
  • 15
    Wang SS, Hildesheim A. Chapter 5: viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003; 31: 35–40.
  • 16
    Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, Pan QJ, Fischer C, Lorincz A, Zahniser D. Shanxi province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001; 83: 439–44.
  • 17
    Belinson JL, Qiao YL, Pretorius RG, Zhang WH, Rong SD, Huang MN, Zhao FH, Wu LY, Ren SD, Huang RD, Washington MF, Pan QJ, et al. Shanxi province cervical cancer screening study. II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int J Gynecol Cancer 2003; 13: 819–26.
    Direct Link:
  • 18
    Blumenthal PD, Gaffikin L, Chirenje ZM, McGrath J, Womack S, Shah K. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int J Gynecol Obstet 2001; 72: 47–53.
  • 19
    Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000; 92: 818–25.
  • 20
    Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT. HPV DNA testing in cervical cancer screening—results from women in a high-risk province of Costa Rica. JAMA 2000; 283: 87–93.
  • 21
    Sankaranarayanan R, Rajkumar R, Theresa R, Esmy PO, Mahé C, Bagyalakshmi KR, Thara S, Frappart L, Lucas E, Muwonge R, Shanthakumari S, Jeevan D, et al. Initial results from a randomised trial of cervical visual screening in rural South India. Int J Cancer 2004; 109: 461–7.
    Direct Link:
  • 22
    Clavel C, Masure L, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 1616–23.
  • 23
    Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P. HPV DNA testing in primary screening of older women. Br J Cancer 1999; 81: 554–8.
  • 24
    Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871–6.
  • 25
    Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities—comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288: 1749–57.
  • 26
    Petry KU, Menton S, Menton M, Loenen-Frosch F, Gomes HD, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, Van Den AE, Iftner T. Inclusion of HPV DNA testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003; 88: 1570–7.
  • 27
    Schneider A, Hoyer H, Lotz B, Leistritz S, Kuhne-Heid R, Nindl I, Muller B, Haerting J, Durst M. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000; 89: 529–34.
    Direct Link:
View Full Article (HTML) Get PDF (403K)